Anti-Ly6g + Ly6c antibody [RB6-8C5] (Ab25377)
Lymphocyte antigen 6G, Ly-6G, Ly-6G.1, Ly6g, Lymphocyte antigen 6C1, Ly-6C1, Ly6c1
详细信息
背景信息
Product Specifications Anti-Ly6g + Ly6c antibody [RB6-8C5] (ab25377) is a rat Monoclonal antibody and is validated for use in Flow Cyt, IHC-Fr, IHC-P in mouse samples. Anti-Ly6g + Ly6c antibody [RB6-8C5] (ab25377) specifically detects Ly6g +Ly6c (UniProt ID: P35461; Molecular weight: 9kDa) and is sold in a convenient trial size to enable initial testing (25 µg) and larger sizes for subsequent scaling up experiments (100 µg). Quality and Validation Abcam's high quality validation processes ensure Anti-Ly6g + Ly6c antibody [RB6-8C5] (ab25377) has high sensitivity and specificity. Anti-Ly6g + Ly6c antibody [RB6-8C5] (ab25377) has been cited over 193 times in peer reviewed journals and is trusted by the scientific community. Anti-Ly6g + Ly6c antibody [RB6-8C5] (ab25377) has 5 independent reviews from customers. Related Products Antibody clone RB6-8C5 is also available pre-conjugated to a variety of labels for your convenience - PE, FITC, APC, PE/Cy7®, Biotin, redFluor™ 710, violetFluor™ 450 ( ab24884, ab25024, ab25273, ab25514, ab25680, ab242065, ab253070 ). This product was changed from ascites to tissue culture supernatant on 2nd March 2020. Lot numbers higher than GR3218400 are from tissue culture supernatant. Please note that the dilutions may need to be adjusted accordingly. If you have any questions, please do not hesitate to contact our scientific support team. REACH authorisation Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances. It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
文献引用 (223)
Inducible CD147 up-regulation boosts extended SARS-CoV-2 infection triggering severe COVID-19 independent of ACE2
诱导型 CD147 上调可延长 SARS-CoV-2 感染,并引发重症 COVID-19,且该过程独立于 ACE2。
Living sensor display implanted on skin for long-term biomarker monitoring.
植入皮肤上的活体传感器显示器,用于长期生物标志物监测。
Hyodeoxycholic acid attenuates atherosclerosis by antagonizing FXR and modulating the PD-1/mTORC1 signaling axis.
脱氧胆酸通过拮抗 FXR 和调节 PD-1/mTORC1 信号轴来减轻动脉粥样硬化。
Neutrophil methylmalonic acid promotes microthrombus formation and adverse cardiac remodeling post-myocardial infarction through activating IL-6 signaling pathway-mediated NETosis.
中性粒细胞甲基丙二酸通过激活IL-6信号通路介导的NETosis,促进心肌梗死后微血栓形成和不良心脏重塑。
IL-10R inhibition induces neutrophil tumoricidal activity.
IL-10R抑制可诱导中性粒细胞的杀瘤活性。
Galectin-9(high) Neutrophils Exacerbate Radiation-Induced Frailty.
高半乳糖凝集素-9中性粒细胞加剧辐射引起的虚弱。
Lymphatic Endothelial C-C Motif Chemokine Ligand 2 Enhances Lymphangiogenesis and Lymphatic Clearance of Macrophages Following Myocardial Infarction.
淋巴内皮 CC 基序趋化因子配体 2 增强心肌梗死后的淋巴管生成和巨噬细胞的淋巴清除。
Neuroimmune Activation in a Goat Model of Intervertebral Disc Degeneration.
神经免疫激活在山羊椎间盘退变模型中的作用。
PLGA nanofibers carrying rhFGF1 for the effective treatment of skin wounds in diabetic mice.
PLGA纳米纤维携带rhFGF1,可有效治疗糖尿病小鼠的皮肤伤口。
Resistance to anti-LAG-3 plus anti-PD-1 therapy in head and neck cancer is mediated by Sox9+ tumor cells interaction with Fpr1+ neutrophils.
头颈癌对 LAG-3 抗 PD-1 疗法的耐药性是由 Sox9+ 肿瘤细胞与 Fpr1+ 中性粒细胞相互作用介导的
- 1
- 2
- 3
- 4
- 5
- 6
- 23